AbCellera Biologics Inc.
11.82USD
+0.4500 (+3.96%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABCL.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 8 | 45 | 9 | 17 | 4 | 5 | 7 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -63 | -58 | -29 | -76 | -50 | -63 | -73 | -94 |
| Net Income | -55 | -43 | -9 | -57 | -35 | -46 | -34 | -51 |
| EPS (Diluted) | -$0.18 | -$0.14 | -$0.03 | -$0.19 | -$0.12 | -$0.15 | -$0.11 | -$0.17 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)